1
|
Kaur D, Behl T, Sehgal A, Singh S, Sharma N, Bungau S. Multifaceted Alzheimer's Disease: Building a Roadmap for Advancement of Novel Therapies. Neurochem Res 2021; 46:2832-2851. [PMID: 34357520 DOI: 10.1007/s11064-021-03415-w] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2021] [Revised: 07/31/2021] [Accepted: 08/02/2021] [Indexed: 12/16/2022]
Abstract
Alzheimer's disease (AD) is one of the most prevailing neurodegenerative disorders of elderly humans associated with cognitive damage. Biochemical, epigenetic, and pathophysiological factors all consider a critical role of extracellular amyloid-beta (Aß) plaques and intracellular neurofibrillary tangles (NFTs) as pathological hallmarks of AD. In an endeavor to describe the intricacy and multifaceted nature of AD, several hypotheses based on the roles of Aß accumulation, tau hyperphosphorylation, impaired cholinergic signaling, neuroinflammation, and autophagy during the initiation and advancement of the disease have been suggested. However, in no way do these theories have the potential of autonomously describing the pathophysiological alterations located in AD. The complex pathological nature of AD has hindered the recognition and authentication of successful biomarkers for the progression of its diagnosis and therapeutic strategies. There has been a significant research effort to design multi-target-directed ligands for the treatment of AD, an approach which is developed by the knowledge that AD is a composite and multifaceted disease linked with several separate but integrated molecular pathways.
Collapse
Affiliation(s)
- Dapinder Kaur
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India
| | - Tapan Behl
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India.
| | - Aayush Sehgal
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India
| | - Sukhbir Singh
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India
| | - Neelam Sharma
- Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India
| | - Simona Bungau
- Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania
| |
Collapse
|
2
|
Mufson EJ, Mahady L, Waters D, Counts SE, Perez SE, DeKosky ST, Ginsberg SD, Ikonomovic MD, Scheff SW, Binder LI. Hippocampal plasticity during the progression of Alzheimer's disease. Neuroscience 2015; 309:51-67. [PMID: 25772787 PMCID: PMC4567973 DOI: 10.1016/j.neuroscience.2015.03.006] [Citation(s) in RCA: 114] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2015] [Revised: 02/05/2015] [Accepted: 03/04/2015] [Indexed: 11/27/2022]
Abstract
Neuroplasticity involves molecular and structural changes in central nervous system (CNS) throughout life. The concept of neural organization allows for remodeling as a compensatory mechanism to the early pathobiology of Alzheimer's disease (AD) in an attempt to maintain brain function and cognition during the onset of dementia. The hippocampus, a crucial component of the medial temporal lobe memory circuit, is affected early in AD and displays synaptic and intraneuronal molecular remodeling against a pathological background of extracellular amyloid-beta (Aβ) deposition and intracellular neurofibrillary tangle (NFT) formation in the early stages of AD. Here we discuss human clinical pathological findings supporting the concept that the hippocampus is capable of neural plasticity during mild cognitive impairment (MCI), a prodromal stage of AD and early stage AD.
Collapse
Affiliation(s)
- E J Mufson
- Barrow Neurological Institute, St. Joseph's Medical Center, Department of Neurobiology, Phoenix, AZ 85013, United States.
| | - L Mahady
- Barrow Neurological Institute, St. Joseph's Medical Center, Department of Neurobiology, Phoenix, AZ 85013, United States
| | - D Waters
- Barrow Neurological Institute, St. Joseph's Medical Center, Department of Neurobiology, Phoenix, AZ 85013, United States
| | - S E Counts
- Department of Translational Science & Molecular Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, United States
| | - S E Perez
- Division of Neurological Sciences, Rush University Medical Center, Chicago, IL, United States
| | - S T DeKosky
- Department of Radiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, United States
| | - S D Ginsberg
- Center for Dementia Research, Nathan Kline Institute, Departments of Psychiatry and Physiology & Neuroscience, New York University Langone Medical Center, Orangeburg, NY, United States
| | - M D Ikonomovic
- Departments of Neurology and Psychiatry, University of Pittsburgh, Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System, Pittsburgh, PA, United States
| | - S W Scheff
- Sanders Brown Center on Aging, University of Kentucky, Lexington, KY, United States
| | - L I Binder
- Department of Translational Science & Molecular Medicine, Michigan State University College of Human Medicine, Grand Rapids, MI, United States
| |
Collapse
|
3
|
Sepulcre J, Sabuncu MR, Becker A, Sperling R, Johnson KA. In vivo characterization of the early states of the amyloid-beta network. ACTA ACUST UNITED AC 2013; 136:2239-52. [PMID: 23801740 DOI: 10.1093/brain/awt146] [Citation(s) in RCA: 90] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Alzheimer's disease is a neurodegenerative disease that is associated with the abnormal accumulation of amyloid-β. Much is known about regional brain atrophy in Alzheimer's disease, yet our knowledge about the network nature of Alzheimer's disease-associated amyloid-β accumulation is limited. We use stepwise connectivity analysis of Pittsburgh Compound B positron emission tomography images to reveal the network properties of amyloid-β deposits in normal elderly subjects and clinical patients with Alzheimer's disease. We found that amyloid-β accumulation in the medial temporal lobe is associated with accumulation in cortical regions such as orbitofrontal, lateral temporal and precuneus/posterior cingulate cortices in Alzheimer's disease. In normal subjects, there was a predominant association between amyloid-β deposits in the hippocampus and the midline prefrontal/orbitofrontal regions, even in those with very low amyloid-β burden. Moreover, the orbitofrontal cortex, amygdala nucleus and hippocampus exhibit hub properties in the amyloid-β network that may be critical to understanding the putative spreading mechanisms of Alzheimer's disease pathology in early stages.
Collapse
Affiliation(s)
- Jorge Sepulcre
- Division of Nuclear Medicine and Molecular Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
| | | | | | | | | |
Collapse
|
4
|
Kamat PK, Rai S, Nath C. Okadaic acid induced neurotoxicity: An emerging tool to study Alzheimer's disease pathology. Neurotoxicology 2013; 37:163-72. [DOI: 10.1016/j.neuro.2013.05.002] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2013] [Revised: 04/25/2013] [Accepted: 05/03/2013] [Indexed: 12/18/2022]
|
5
|
Abstract
Non-human primates have a small but important role in basic and translational biomedical research, owing to similarities with human beings in physiology, cognitive capabilities, neuroanatomy, social complexity, reproduction, and development. Although non-human primates have contributed to many areas of biomedical research, we review here their unique contributions to work in neuroscience, and focus on four domains: Alzheimer's disease, neuroAIDS, Parkinson's disease, and stress. Our discussion includes, for example, the role of non-human primates in development of new treatments (eg, stem cells, gene transfer) before phase I clinical trials in patients; basic research on disease pathogenesis; and understanding neurobehavioural outcomes resulting from genotype-environment interactions.
Collapse
Affiliation(s)
- John P Capitanio
- California National Primate Research Center and Department of Psychology, University of California, Davis, CA 95616, USA.
| | | |
Collapse
|
6
|
Bell KFS, Bennett DA, Cuello AC. Paradoxical upregulation of glutamatergic presynaptic boutons during mild cognitive impairment. J Neurosci 2007; 27:10810-7. [PMID: 17913914 PMCID: PMC6672819 DOI: 10.1523/jneurosci.3269-07.2007] [Citation(s) in RCA: 103] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Synaptic integrity is now recognized as a central component of Alzheimer's disease. Surprisingly, however, the structural status of glutamatergic synapses in Alzheimer's disease is unclear, despite the fact that glutamate is the major excitatory transmitter of the CNS and has key roles in excitotoxicity and long-term potentiation. The identification of specific markers of glutamatergic neurons now allows an assessment of the structural involvement of the glutamatergic system across progressive stages of the Alzheimer's pathology, an opportunity not afforded by previously used neurochemical approaches. Glutamatergic presynaptic bouton density and dystrophic neurite abundance were quantified in midfrontal gyrus brain tissue from subjects with no cognitive impairment, mild cognitive impairment, or mild- or severe-stage Alzheimer's disease. Our study demonstrates a striking pathology-dependent pattern of glutamatergic synaptic remodeling with disease progression. Subjects with mild cognitive impairment display a paradoxical elevation in glutamatergic presynaptic bouton density, a situation akin to that observed in the cholinergic system, which then depletes and drops with disease progression. This pattern of synaptic remodeling mirrors our previous findings in transgenic animal models and is of major relevance to current transmitter-based therapeutics.
Collapse
Affiliation(s)
| | - David A. Bennett
- Rush Alzheimer's Disease Center, Armour Academic Center, Chicago, Illinois 60612
| | - A. Claudio Cuello
- Departments of Pharmacology and Therapeutics
- Anatomy and Cell Biology, and
- Neurology and Neurosurgery, McGill University, Montreal, Quebec, Canada H3G 1Y6, and
| |
Collapse
|
7
|
Kirvell SL, Esiri M, Francis PT. Down-regulation of vesicular glutamate transporters precedes cell loss and pathology in Alzheimer's disease. J Neurochem 2006; 98:939-50. [PMID: 16893425 DOI: 10.1111/j.1471-4159.2006.03935.x] [Citation(s) in RCA: 132] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Alzheimer's disease (AD) is characterized pathologically by plaques, tangles, and cell and synapse loss. As glutamate is the principle excitatory neurotransmitter of the CNS, the glutamatergic system may play an important role in AD. An essential step in glutamate neurotransmission is the concentration of glutamate into synaptic vesicles before release from the presynaptic terminal. Recently a group of proteins responsible for uptake has been identified - the vesicular glutamate transporters (VGLUTs). The generation of antibodies has facilitated the study of glutamatergic neurones. Here, we used antibodies to the VGLUTs together with immunohistochemistry and western blotting to investigate the status of glutamatergic neurones in temporal, parietal and occipital cortices of patients with AD; these regions were chosen to represent severely, moderately and mildly affected regions at the end stage of the disease. There was no change in expression of the synaptic markers in relation to total protein in the temporal cortex, but a significant reduction in synaptophysin and VGLUT1 was found in both the parietal and occipital cortices. These changes were found to relate to the number of tangles in the temporal cortex. There were no correlations with either mental test score or behaviour syndromes, with the exception of depression.
Collapse
Affiliation(s)
- Sara L Kirvell
- Wolfson Centre for Age-Related Diseases, Kings College London, London, UK
| | | | | |
Collapse
|
8
|
Nishida A, Iwata H, Kudo Y, Kobayashi T, Matsuoka Y, Kanai Y, Endou H. Nicergoline Enhances Glutamate Uptake via Glutamate Transporters in Rat Cortical Synaptosomes. Biol Pharm Bull 2004; 27:817-20. [PMID: 15187425 DOI: 10.1248/bpb.27.817] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
To elucidate the mechanisms of neuroprotective action of nicergoline, we examined its effect on glutamate transport in rat cortical synaptosomes and cloned glutamate transporters. In synaptosomes, nicergoline enhanced the glutamate uptake at 1-10 microM in standard medium and suppressed the increase of extracellular glutamate by reversed transport in low Na(+) medium. Apparent increase of extracellular glutamate concentration by dihydrokinate, an inhibitor of glial glutamate transporter GLT-1, was antagonized by nicergoline. In Xenopus oocytes expressing mouse neuronal glutamate transporter (mEAAC1), the glutamate-induced inward current was enhanced by nicergoline. These results suggest that nicergoline reduces the extracellular glutamate concentration through its effect on glutamate transporters.
Collapse
Affiliation(s)
- Atsushi Nishida
- Discovery and Pharmacology Research Laboratories, Tanabe Seiyaku Co., Ltd., Toda, Saitama, Japan.
| | | | | | | | | | | | | |
Collapse
|
9
|
Abstract
Glutamate is the major transmitter of the brain and is involved in all aspects of cognitive function since it is the transmitter of cortical and hippocampal pyramidal neurones. Furthermore, glutamate and glutamate receptors are involved in long-term potentiation, a process believed to underlie learning and memory. Histological studies indicate loss of pyramidal neurones and their synapses in Alzheimer's disease (AD), this together with biochemical evidence suggests presynaptic (and postsynaptic) glutamatergic hypoactivity. This represents a 'double blow' as the activity of glutamatergic neurones is heavily influenced by the cholinergic system, which is also dysfunctional in AD. The clinical relevance of these changes is emphasised because glutamatergic and cholinergic dysfunction are strong correlates of cognitive decline in AD. The mechanism by which glutamatergic (and cholinergic) cells die is likely to be a combination of necrosis and apoptosis caused by a range of factors which include tangle formation and the effects of too much and too little glutamatergic neurotransmission.
Collapse
Affiliation(s)
- Paul T Francis
- Centre for Neuroscience Research, King's College London, London, UK.
| |
Collapse
|
10
|
Abstract
The number of people with Alzheimer's disease has never been greater and is set to increase substantially in the decades ahead as the proportion of the population aged 65 years or more rises sharply. There is, therefore, a substantial and increasing need for effective pharmacotherapy. Increased understanding of disease pathophysiology has led to palliative treatments for both cognitive and non-cognitive changes in behaviour. This, together with the prospect of drugs that slow or perhaps even halt the course of the disease, raises hope that this devastating disorder will soon be more amenable to pharmacotherapy with new drugs that either ameliorate specific symptoms or alter the course of the disease.
Collapse
|
11
|
Mann MB, Wu S, Rostamkhani M, Tourtellotte W, MacMurray J, Comings DE. Phenylethanolamine N-methyltransferase (PNMT) gene and early-onset Alzheimer disease. AMERICAN JOURNAL OF MEDICAL GENETICS 2001; 105:312-6. [PMID: 11378842 DOI: 10.1002/ajmg.1363] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
The activity of human phenylethanolamine N-methyltransferase (PNMT) is reduced in the neurons of those cells in many subcortical areas of the brain that are known to undergo neurodegeneration in Alzheimer disease (AD). Others have reported that PNMT is decreased in brains of persons with AD and that the decrease in enzymatic activity is due to a reduced amount of the enzyme protein. We have previously described two polymorphisms, G-353A and G-148A, in the promoter region of the gene coding for PNMT. These markers were tested for their association with the occurrence of sporadic AD. Genotyping of 131 necropsy confirmed AD cases, and 947 adult nondemented controls were completed. We observed a significant association between both of the PNMT gene polymorphisms and early-onset AD (EOAD) (P < or = 0.007), but not in late-onset AD (LOAD). These data suggest that genetic variation in the promoter of the PNMT gene is associated with increased susceptibility to the sporadic form of EOAD.
Collapse
Affiliation(s)
- M B Mann
- Department of Medical Genetics, City of Hope Medical Center, Duarte, California, USA
| | | | | | | | | | | |
Collapse
|
12
|
Salehi A, Verhaagen J, Swaab DF. Neurotrophin receptors in Alzheimer's disease. PROGRESS IN BRAIN RESEARCH 1999; 117:71-89. [PMID: 9932402 DOI: 10.1016/s0079-6123(08)64009-1] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Affiliation(s)
- A Salehi
- Netherlands Institute for Brain Research, Amsterdam, The Netherlands.
| | | | | |
Collapse
|
13
|
Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999; 66:137-47. [PMID: 10071091 PMCID: PMC1736202 DOI: 10.1136/jnnp.66.2.137] [Citation(s) in RCA: 1367] [Impact Index Per Article: 54.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Alzheimer's disease is one of the most common causes of mental deterioration in elderly people, accounting for around 50%-60% of the overall cases of dementia among persons over 65 years of age. The past two decades have witnessed a considerable research effort directed towards discovering the cause of Alzheimer's disease with the ultimate hope of developing safe and effective pharmacological treatments. This article examines the existing scientific applicability of the original cholinergic hypothesis of Alzheimer's disease by describing the biochemical and histopathological changes of neurotransmitter markers that occur in the brains of patients with Alzheimer's disease both at postmortem and neurosurgical cerebral biopsy and the behavioural consequences of cholinomimetic drugs and cholinergic lesions. Such studies have resulted in the discovery of an association between a decline in learning and memory, and a deficit in excitatory amino acid (EAA) neurotransmission, together with important roles for the cholinergic system in attentional processing and as a modulator of EAA neurotransmission. Accordingly, although there is presently no "cure" for Alzheimer's disease, a large number of potential therapeutic interventions have emerged that are designed to correct loss of presynaptic cholinergic function. A few of these compounds have confirmed efficacy in delaying the deterioration of symptoms of Alzheimer's disease, a valuable treatment target considering the progressive nature of the disease. Indeed, three compounds have received European approval for the treatment of the cognitive symptoms of Alzheimer's disease, first tacrine and more recently, donepezil and rivastigmine, all of which are cholinesterase inhibitors.
Collapse
Affiliation(s)
- P T Francis
- Dementia Research Laboratory, Neuroscience Research Centre, Guy's, King's and St Thomas' Schools of Biomedical Sciences, King's College, London, UK.
| | | | | | | |
Collapse
|
14
|
Abstract
Following a brief introduction and discussion of the pathological features of Alzheimer's disease, the main emphasis of this review article will be the genetic factors that have been implicated in this disease. These can be divided into two main categories. First, the three genes in which mutations are known to result in early onset autosomal dominant familial Alzheimer's disease will be discussed. These are well characterised but account for only a small proportion of Alzheimer's disease cases. Late onset, sporadic Alzheimer's disease is more common and evidence suggests that there is a genetic component to this type of disease. A number of genetic risk factors have been implicated that might increase the risk of developing sporadic disease. Many of these are controversial and studies have shown conflicting results, which are discussed in this section. Finally, a brief discussion of some of the mechanisms suggested to play a role in the pathogenesis of Alzheimer's disease is included. It is hoped that this will show why particular genes have been implicated in Alzheimer's disease and how they might be able to influence the development of the disease.
Collapse
Affiliation(s)
- L Tilley
- Division of Clinical Chemistry, School of Clinical Laboratory Sciences, Queen's Medical Centre, University of Nottingham, UK
| | | | | |
Collapse
|
15
|
Yin KJ, Yan YP, Sun FY. Altered expression of glutamate transporter GLAST mRNA in rat brain after photochemically induced focal ischemia. Anat Rec (Hoboken) 1998; 251:9-14. [PMID: 9605214 DOI: 10.1002/(sici)1097-0185(199805)251:1<9::aid-ar3>3.0.co;2-x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND The neurotransmitter glutamate is involved in fast excitatory synaptic transmission in the mammalian brain. Glutamate released from presynaptic terminals must be removed rapidly from the synaptic cleft by high affinity, sodium-dependent glutamate transporters to keep the extracellular glutamate concentration low to protect neuron from glutamate excitotoxicity, which is the major pathological mechanism of brain ischemia. GLAST is one of the identified four subtypes of the glutamate transporter system and has been suggested to play an important role in some pathological conditions. But until recently, very little information existed the concerning relationship between GLAST expression and cerebral ischemia. METHODS Nonradioactive in situ hybridization was employed to evaluate the changes of glutamate transporter GLAST mRNA expression in rat cerebral cortex and hippocampus following photochemically induced focal cortical ischemia. RESULTS GLAST mRNA expression in cerebral pyramid cells below the infarcted area did not change at 3 h, significantly decreased at 12 h, recovered to the control level at 24 h, and significantly increased at 72 h following the ischemic lesion. No changes in GLAST mRNA expression were observed in all subfields of the hippocampal complex. CONCLUSIONS The present findings suggest that the time-course changes of GLAST mRNA expression after ischemia may be correlated with the pathogenesis of photosensitive ischemic brain damage.
Collapse
Affiliation(s)
- K J Yin
- Department of Neurobiology, Shanghai Medical University, People's Republic of China
| | | | | |
Collapse
|
16
|
Sigurdsson EM, Lee JM, Dong XW, Hejna MJ, Lorens SA. Bilateral injections of amyloid-beta 25-35 into the amygdala of young Fischer rats: behavioral, neurochemical, and time dependent histopathological effects. Neurobiol Aging 1997; 18:591-608. [PMID: 9461057 DOI: 10.1016/s0197-4580(97)00154-1] [Citation(s) in RCA: 72] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
To examine the time course of the histopathological effects of bilateral injections of amyloid-beta 25-35 (A beta) and to determine if these effects are associated with a reduction in choline acetyltransferase activity and behavioral impairments, we injected A beta (5.0 nmol) into the amygdala of young male Fischer rats. Control rats received vehicle infusions. For histological analysis, animals were sacrificed at 8, 32, 64, 96, and 128 days postoperatively (n = 21-33 per timepoint). A beta induced neuronal tau-2 staining in the right, but not the left amygdala and hippocampus. A beta also induced reactive astrocytosis and neuronal shrinkage within the right hippocampus and amygdala, respectively. As with tau-2, these same brain regions within the left hemisphere in the A beta-treated rats were significantly less affected. In addition, A beta appeared to induce microglial and neuronal interleukin-1beta staining. The histopathological effects of A beta peaked at 32 days postoperatively but were not associated with a reduction in amygdaloid choline acetyltransferase activity. In a separate experiment, behavioral effects of bilateral intra-amygdaloid injections of A beta were analyzed at 34-52 days postoperatively. In an open field test, the treatment groups differed only in the numbers of rears emitted (p = 0.016). There was no effect of A beta in the Morris water maze or in the acquisition and retention of a one-way conditioned avoidance response. These data suggest a laterality in the histopathological effects of A beta and that the effects of single injections are in part transient. These findings also suggest a direct association between plaque and tangle formation in Alzheimer's disease, and support the use of this rat model to screen drugs that may alter the initial pathological events associated with Alzheimer's disease, that occur before the manifestations of extensive behavioral impairments become evident.
Collapse
Affiliation(s)
- E M Sigurdsson
- Department of Pharmacology, Loyola University of Chicago Medical Center, Maywood, IL 60153, USA
| | | | | | | | | |
Collapse
|
17
|
Elovic E, Antoinette T. Principles of Neurochemistry and Neuropharmacology. Phys Med Rehabil Clin N Am 1997. [DOI: 10.1016/s1047-9651(18)30293-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
18
|
Abstract
The past decade has witnessed an enormous increase in our knowledge of the variety and complexity of neuropathological and neurochemical changes in Alzheimer's disease. Although the disease is characterized by multiple deficits of neurotransmitters in the brain, this overview emphasizes the structural and neurochemical localization of the elements of the acetylcholine system (choline acetyltransferase, acetylcholinesterase, and muscarinic and nicotinic acetylcholine receptors) in the non-demented brain and in Alzheimer's disease brain samples. The results demonstrate a great variation in the distribution of acetylcholinesterase, choline acetyltransferase, and the nicotinic and muscarinic acetylcholine receptors in the different brain areas, nuclei and subnuclei. When stratification is present in certain brain regions (olfactory bulb, cortex, hippocampus, etc.), differences can be detected as regards the laminar distribution of the elements of the acetylcholine system. Alzheimer's disease involves a substantial loss of the elements of the cholinergic system. There is evidence that the most affected areas include the cortex, the entorhinal area, the hippocampus, the ventral striatum and the basal part of the forebrain. Other brain areas are less affected. The fact that the acetylcholine system, which plays a significant role in the memory function, is seriously impaired in Alzheimer's disease has accelerated work on the development of new drugs for treatment of the disease of the 20th century.
Collapse
Affiliation(s)
- P Kása
- Alzheimer's Disease Research Center, Albert Szent-Györgyi Medical University, Szeged, Hungary.
| | | | | |
Collapse
|
19
|
Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, Okuyama S, Kawashima N, Hori S, Takimoto M, Wada K. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 1997; 276:1699-702. [PMID: 9180080 DOI: 10.1126/science.276.5319.1699] [Citation(s) in RCA: 1334] [Impact Index Per Article: 49.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Extracellular levels of the excitatory neurotransmitter glutamate in the nervous system are maintained by transporters that actively remove glutamate from the extracellular space. Homozygous mice deficient in GLT-1, a widely distributed astrocytic glutamate transporter, show lethal spontaneous seizures and increased susceptibility to acute cortical injury. These effects can be attributed to elevated levels of residual glutamate in the brains of these mice.
Collapse
Affiliation(s)
- K Tanaka
- Department of Degenerative Neurological Diseases, National Institute of Neuroscience, Kodaira, Tokyo 187, Japan.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
|
21
|
Sigurdsson EM, Lorens SA, Hejna MJ, Dong XW, Lee JM. Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 rats. Neurobiol Aging 1996; 17:893-901. [PMID: 9363801 DOI: 10.1016/s0197-4580(96)00169-8] [Citation(s) in RCA: 47] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
To determine if amyloid-beta (A beta) induces tau-immunoreactivity (IR) and reactive astrocytosis in vivo, we injected A beta 25-35 (5.0 nmol) into the right amygdala of rats. At 8 days postinjection, the peptide induced tau-2 IR in neuronal cell bodies and processes ipsilaterally in the amygdala, cingulate cortex, and hippocampus. At 32 days postinjection, the intensity of tau-2 IR was greater than at 8 days in the amygdala and hippocampus, but not in the cingulate cortex. Induction of Alz-50 IR also was progressive but the morphology and distribution was different from tau-2 IR. Beaded fibers with occasional neuronal perikarya were visualized with Alz-50, and the IR was primarily observed in the ipsilateral amygdala. In addition, amygdaloid injections of A beta 25-35 induced reactive astrocytosis, particularly in the ipsilateral hippocampus at 32 days postoperatively. To our knowledge, this is the first study to show that in vivo injections of A beta 25-35 induce progressive transsynaptic cytoskeletal and astrogliotic reactions, that gradually spread from the area of injection to brain regions that have prominent efferent connections with that area. These findings also suggest a direct association between plaque and tangle formation in Alzheimer's disease.
Collapse
Affiliation(s)
- E M Sigurdsson
- Department of Pharmacology, Loyola University Chicago Medical Center, Maywood, IL 60153, USA
| | | | | | | | | |
Collapse
|
22
|
Nakayama T, Kawakami H, Tanaka K, Nakamura S. Expression of three glutamate transporter subtype mRNAs in human brain regions and peripheral tissues. BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH 1996; 36:189-92. [PMID: 9011758 DOI: 10.1016/0169-328x(95)00297-6] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
We compared the expression of mRNAs for three human glutamate transporter subtypes in human central nervous system (CNS) and other organs by Northern blot analysis. hGLT-1 and hGLuT-1 mRNAs were most abundantly expressed in the brain, while hEAAC1 mRNA expression (3.8 kb and 2,4 kb) was strongest in peripheral organs. All subtype mRNAs were expressed throughout the CNS with hGLT-1 predominant in frontal lobe, striatum and limbic areas, and hGluT-1 predominant in cerebellum.
Collapse
Affiliation(s)
- T Nakayama
- Third Department of Internal Medicine, Hiroshima University, School of Medicine, Japan
| | | | | | | |
Collapse
|
23
|
Gsell W, Strein I, Riederer P. The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. JOURNAL OF NEURAL TRANSMISSION. SUPPLEMENTUM 1996; 47:73-101. [PMID: 8841958 DOI: 10.1007/978-3-7091-6892-9_5] [Citation(s) in RCA: 24] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
We present the results of a meta-analysis of neurochemical changes in human post mortem brains of Alzheimer type (AD), vascular type (VD) and mixed type (MF) dementias, and matched controls based on 275 articles published between January 1980 and February 1994. Severity of degeneration between the different neurochemical systems is as follows, although ranking is difficult with regard to limited numbers of investigations in some neurochemical systems: Cholinergic system > serotonergic system > excitatory amino acids > GABAergic system > energy metabolism > NA > oxidative stress parameters > neuropeptides > DA. But, within a neurochemical system, degeneration is not evenly distributed. Spared parameters, e.g. muscarinic receptors and MAO-B, allow to make some suggestions for future therapeutic strategies.
Collapse
Affiliation(s)
- W Gsell
- Department of Psychiatry, University of Würzburg, Federal Republic of Germany
| | | | | |
Collapse
|
24
|
Blokland A. Acetylcholine: a neurotransmitter for learning and memory? BRAIN RESEARCH. BRAIN RESEARCH REVIEWS 1995; 21:285-300. [PMID: 8806017 DOI: 10.1016/0165-0173(95)00016-x] [Citation(s) in RCA: 418] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
The cholinergic hypothesis claims that the decline in cognitive functions in dementia is predominantly related to a decrease in cholinergic neurotransmission. This hypothesis has led to great interest in the putative involvement of the cholinergic neurotransmission in learning and memory processes. This review aims to assess the data of studies in which the role of acetylcholine (ACh) in cognitive functions was investigated. For this purpose, studies from three different fields of research, namely: (1) behavioral pharmacology (effects of drugs on behavior); (2) behavioral neuroscience (effects of brain lesions on behavior); and (3) dementia, are discussed separately. The experimental tools that have been used in pharmacological studies may appear to be inadequate to enable conclusions to be drawn about the involvement of ACh in learning and memory processes. Especially, the use of scopolamine as a pharmacological tool is criticized. In the field of behavioral neuroscience a highly specific cholinergic toxin has been developed. It appears that the greater and more specific the cholinergic damage, the fewer effects can be observed at the behavioral level. The correlation between the decrease in cholinergic markers and the cognitive decline in dementia may not be as clearcut as has been assumed. The involvement of other neurotransmitter systems in cognitive functions is briefly discussed. Taking into account the results of the different fields of research, the notion that ACh plays a pivotal role in learning and memory processes seems to be overstated. Even when the role of other neurotransmitter systems in learning and memory is taken into consideration, it is unlikely that ACh has a specific role in these processes. On basis of the available data, ACh seems to be more specifically involved in attentional processes than in learning and memory processes.
Collapse
Affiliation(s)
- A Blokland
- Institute for Neurobiology, Troponwerke, Köln, Germany
| |
Collapse
|
25
|
Mukainaka Y, Tanaka K, Hagiwara T, Wada K. Molecular cloning of two glutamate transporter subtypes from mouse brain. BIOCHIMICA ET BIOPHYSICA ACTA 1995; 1244:233-7. [PMID: 7766664 DOI: 10.1016/0304-4165(95)00062-g] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The physiological action of glutamate is terminated by diffusional processes with its subsequent removal by high-affinity transport systems localized to glial and/or neuronal elements. Several cDNAs encoding glutamate transporters have been isolated from mammalian tissues. Here, we screened a cDNA library derived from mouse cerebellum and isolated the two glutamate transporters, termed MGLT1 and MEAAC1. The MGLT1 and MEAAC1 cDNAs encode proteins of 572 and 523 amino acids, respectively. MGLT1 has 93.9% amino acid sequence identity with the rat GLT1 and MEAAC1 has 89.3% identity with the rabbit EAAC1. MEAAC1 mRNA was expressed in brain, lung, kidney and skeletal muscle, whereas expression of MGLT1 was restricted to brain.
Collapse
Affiliation(s)
- Y Mukainaka
- Department of Degenerative Neurological Diseases, National Institute of Neuroscience, Tokyo, Japan
| | | | | | | |
Collapse
|
26
|
Alonso JR, Amaral DG. Cholinergic innervation of the primate hippocampal formation. I. Distribution of choline acetyltransferase immunoreactivity in the Macaca fascicularis and Macaca mulatta monkeys. J Comp Neurol 1995; 355:135-70. [PMID: 7608341 DOI: 10.1002/cne.903550202] [Citation(s) in RCA: 51] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
The cholinergic innervation of the hippocampal formation of Macaca fascicularis (cynomolgus) and Macaca mulatta (rhesus) monkeys was investigated by immunohistochemical procedures using a monoclonal antibody directed against choline acetyltransferase. The distribution of choline acetyltransferase in the monkey demonstrated both similarities and differences with the staining patterns observed in the rat or with acetylcholinesterase in the monkey. While both of these latter preparations demonstrated labeled cells, for example, no choline acetyltransferase labeled neurons were observed in the monkey hippocampal formation. Choline acetyltransferase activity was restricted to fibers which varied in thickness and number of varicosities and in their regional and laminar distribution. The highest densities of labeled fibers were observed in the uncal portion of the hippocampus, in the parasubiculum, and in the entorhinal cortex; the lowest densities of labeled fibers were observed in CA1 and in midrostrocaudal levels of the dentate gyrus. In the dentate gyrus, immunoreactive fibers were densely distributed in the molecular layer and in an infragranular plexus. One of the few striking noticeable interspecies differences was observed in the dentate gyrus. In the rhesus monkey, labeled fibers in the molecular layer were divided into a superficial denser and an inner lighter lamina, whereas in M. fascicularis, the cholinergic fibers were distributed more homogeneously throughout the molecular layer. In the hippocampus proper, there was a progressive decrease in the density of ChAT-immunoreactive fibers from CA3/CA2 into CA1. The subiculum also demonstrated modest labeling which was nonetheless higher than in CA1; the border of these fields demonstrated increased fiber labeling. The density of choline acetyltransferase staining was high in the presubiculum and parasubiculum. In the entorhinal cortex, a relatively clear boundary was observed between the more heavily stained superficial layers (I, II, and III) and the more weakly labeled deep layers (V and VI), especially in the intermediate and caudal fields. A transverse decreasing gradient was observed with the densest plexus of cholinergic fibers found in the medially situated olfactory field of the entorhinal cortex and the lowest density in the laterally located caudal and lateral fields.
Collapse
Affiliation(s)
- J R Alonso
- Universidad de Salamanca, Departamento de Biología Celular y Patología, Spain
| | | |
Collapse
|
27
|
Wiley RG, Berbos TG, Deckwerth TL, Johnson EM, Lappi DA. Destruction of the cholinergic basal forebrain using immunotoxin to rat NGF receptor: modeling the cholinergic degeneration of Alzheimer's disease. J Neurol Sci 1995; 128:157-66. [PMID: 7738592 DOI: 10.1016/0022-510x(94)00226-e] [Citation(s) in RCA: 60] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Degeneration of cholinergic neurons in the basal forebrain (CBF) is a prominent neuropathological feature of Alzheimer's disease and is thought responsible for some cognitive deficits seen in patients. An animal model of pure CBF degeneration would be valuable for analysis of the function of these neurons and testing therapeutic strategies. CBF neurons express receptors for nerve growth factor. In order to selectively destroy these neurons, we developed an immunotoxin using monoclonal antibody (192 IgG) to rat NGF receptor (p75NGFr) armed with the ribosome inactivating protein, saporin. In vitro 192-saporin was highly toxic to neurons expressing p75NGFr. Intraventricular injections of 192-saporin destroyed the CBF and impaired passive avoidance learning. These results indicate that 192-saporin treated rats can be used to model a key feature of Alzheimer's disease and that anti-neuronal immunotoxins are a powerful approach to selective neural lesioning.
Collapse
MESH Headings
- Alzheimer Disease
- Animals
- Antibodies, Monoclonal/administration & dosage
- Antibodies, Monoclonal/toxicity
- Avoidance Learning/physiology
- Basal Ganglia/drug effects
- Basal Ganglia/pathology
- Basal Ganglia/physiopathology
- Behavior, Animal/physiology
- Cell Count
- Cells, Cultured
- Cholinergic Fibers/drug effects
- Cholinergic Fibers/pathology
- Disease Models, Animal
- Ganglia, Sympathetic/cytology
- Ganglia, Sympathetic/drug effects
- Humans
- Immunoconjugates
- Immunoglobulin G/immunology
- Immunotoxins/administration & dosage
- Immunotoxins/toxicity
- Injections, Intraventricular
- Learning Disabilities/chemically induced
- Male
- Membrane Glycoproteins/drug effects
- Membrane Glycoproteins/immunology
- N-Glycosyl Hydrolases
- Neurons/drug effects
- Plant Proteins/administration & dosage
- Plant Proteins/toxicity
- Rats
- Rats, Sprague-Dawley
- Receptor, Nerve Growth Factor
- Receptors, Nerve Growth Factor/drug effects
- Receptors, Nerve Growth Factor/immunology
- Ribosome Inactivating Proteins, Type 1
- Saporins
- Septum Pellucidum/drug effects
- Septum Pellucidum/pathology
- Septum Pellucidum/physiopathology
- Substantia Innominata/drug effects
- Substantia Innominata/pathology
- Substantia Innominata/physiopathology
Collapse
Affiliation(s)
- R G Wiley
- Laboratory of Experimental Neurology, DVAMC, Nashville, TN 37212-2637, USA
| | | | | | | | | |
Collapse
|
28
|
Mallet PE, Beninger RJ, Flesher SN, Jhamandas K, Boegman RJ. Nucleus basalis lesions: implication of basoamygdaloid cholinergic pathways in memory. Brain Res Bull 1995; 36:51-6. [PMID: 7882049 DOI: 10.1016/0361-9230(94)00162-t] [Citation(s) in RCA: 36] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Previous studies have shown a lack of association between cortical choline acetyltransferase (ChAT) activity and severity of memory impairment following excitotoxic lesions of the nucleus basalis magnocellularis (NBM). It recently has been proposed that the differential effects of NBM injections of various excitotoxins on amygdaloid and cortical ChAT may explain this result. The present study evaluated the mnemonic effect of unilateral intra-NBM infusions of the excitotoxins phthalic acid and quisqualic acid, which decrease ChAT activity primarily in the amygdala and cortex, respectively. Rats were trained in a double Y-maze, lesioned, and allowed to recover for 1 week prior to memory assessment. Behavioral results showed impaired working but not reference memory following phthalic acid lesions, and no significant effect following quisqualic acid lesions. Biochemical analysis in a second group of subjects confirmed that phthalic acid lesions produced a large decrease in basolateral amygdaloid ChAT, but had little effect on cortical ChAT activity. Conversely, quisqualic acid lesions produced a large decrease in cortical, but not basolateral amygdaloid, ChAT activity. These results suggest that the NBM amygdalopetal cholinergic pathways play a role in mnemonic functioning.
Collapse
Affiliation(s)
- P E Mallet
- Department of Psychology, Queen's University, Kingston, Canada
| | | | | | | | | |
Collapse
|
29
|
Borowsky B, Hoffman BJ. Neurotransmitter transporters: molecular biology, function, and regulation. INTERNATIONAL REVIEW OF NEUROBIOLOGY 1995; 38:139-99. [PMID: 8537200 DOI: 10.1016/s0074-7742(08)60526-7] [Citation(s) in RCA: 79] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- B Borowsky
- Unit on Molecular Pharmacology, National Institute of Mental Health, Bethesda, Maryland 20892-4090, USA
| | | |
Collapse
|
30
|
Kwo-On-Yuen PF, Newmark RD, Budinger TF, Kaye JA, Ball MJ, Jagust WJ. Brain N-acetyl-L-aspartic acid in Alzheimer's disease: a proton magnetic resonance spectroscopy study. Brain Res 1994; 667:167-74. [PMID: 7697354 DOI: 10.1016/0006-8993(94)91494-x] [Citation(s) in RCA: 50] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
This study was performed in order to measure changes in brain N-acetyl-L-aspartic acid (NAA) in post-mortem brain tissue in Alzheimer's disease (AD) in comparison to normal control subjects using the technique of magnetic resonance spectroscopy. Brain tissue was obtained at autopsy and frozen until use, from seven patients diagnosed according to current research criteria for AD and 7 control subjects. Detailed clinical evaluations were available for all the dementia cases. Representative brain samples were obtained from three neocortical regions and a limbic region (parahippocampal gyrus) in white and grey matter. NAA was quantified on perchloric acid extracts using proton nuclear magnetic resonance (NMR) spectroscopy. Regional NAA did not vary significantly with age. In AD, reductions were present in the grey matter of the neocortex but not in the white matter. Within the parahippocampal gyrus there were reductions in both tissue types; only cortical levels correlated with clinical scales of dementia severity. A pattern of increasing correlation was observed between dementia severity as measured by the mini mental state examination during life and NAA levels from brain areas of increasing pathological predilection in AD. These post-mortem studies show reductions in brain NAA in AD which correlate with dementia severity during life and which support the use of future in vivo NAA spectroscopic images in the evaluation of AD patients.
Collapse
Affiliation(s)
- P F Kwo-On-Yuen
- Center for Functional Imaging, Lawrence Berkeley Laboratory, Berkeley, CA 94720
| | | | | | | | | | | |
Collapse
|
31
|
Abstract
Alzheimer disease and related dementias, in common with most major neurological diseases, are characterized by localized brain damage. An abundance of senile plaques and neurofibrillary tangles in certain brain areas is pathognomic of the disease: of the two, the density of tangles may correlate more closely with disease severity ante mortem. Clinical manifestation of the disease also results from a locally severe loss of neurones. This might be caused by over-stimulation by excitant amino acid transmitters such as glutamate, which would promote cell death. Mechanisms which might give rise to the localization of Alzheimer pathogenesis include hypersensitivity to damage because a cell carries a particular sub-set of post-synaptic receptors; local variations in the efficiency of excitatory amino acid transport; and, possibly, local exacerbation of toxicity by substances such as beta-amyloid. Elucidation of such mechanisms could lead to new pharmacotherapies of dementia.
Collapse
Affiliation(s)
- P R Dodd
- Clinical Research Laboratory, Royal Brisbane Hospital Foundation, Australia
| | | | | |
Collapse
|
32
|
Abstract
Nerve growth factor (NGF) is a well-characterized protein that exerts pharmacological effects on a group of cholinergic neurons known to atrophy in Alzheimer's disease (AD). Considerable evidence from animal studies suggests that NGF may be useful in reversing, halting, or at least slowing the progression of AD-related cholinergic basal forebrain atrophy, perhaps even attenuating the cognitive deficit associated with the disorder. However, many questions remain concerning the role of NGF in AD. Levels of the low-affinity receptor for NGF appear to be at least stable in AD basal forebrain, and the recent finding of AD-related increases in cortical NGF brings into question whether endogenous NGF levels are related to the observed cholinergic atrophy and whether additional NGF will be useful in treating this disorder. Evidence regarding the localization of NGF within the central nervous system and its presumed role in maintaining basal forebrain cholinergic neurons is summarized, followed by a synopsis of the relevant aspects of AD neuropathology. The available data regarding levels of NGF and its receptor in the AD brain, as well as potential roles for NGF in the pathogenesis and treatment of AD, are also reviewed. NGF and its low affinity receptor are abundantly present within the AD brain, although this does not rule out an NGF-related mechanism in the degeneration of basal forebrain neurons, nor does it eliminate the possibility that exogenous NGF may be successfully used to treat AD. Further studies of the degree and distribution of NGF within the human brain in normal aging and in AD, and of the possible relationship between target NGF levels and the status of basal forebrain neurons in vivo, are necessary before engaging in clinical trials.
Collapse
Affiliation(s)
- S A Scott
- Department of Neurosurgery, University of Cincinnati, Ohio 45267-0515
| | | |
Collapse
|
33
|
Bridges RJ, Lovering FE, Koch H, Cotman CW, Chamberlin AR. A conformationally constrained competitive inhibitor of the sodium-dependent glutamate transporter in forebrain synaptosomes: L-anti-endo-3,4-methanopyrrolidine dicarboxylate. Neurosci Lett 1994; 174:193-7. [PMID: 7970177 DOI: 10.1016/0304-3940(94)90019-1] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
A series of L-3,4-methanopyrrolidine dicarboxylate isomers were investigated as potential inhibitors of the high affinity, sodium-dependent glutamate transporter in rat forebrain synaptosomes. Of the isomers tested, only L-anti-endo-3,4-methanopyrrolidine dicarboxylate (L-anti-endo-MPDC) blocked the uptake of [3H]D-aspartate, a non-metabolized substrate. Kinetic analysis demonstrated that L-anti-endo-MPDC is a potent competitive inhibitor (Ki = 5 microM) comparable to that of L-glutamate and L-trans-2,4-pyrrolidine dicarboxylate (L-trans-2,4-PDC). Conformational analysis of L-glutamate, L-trans-2,4-PDC and L-anti-endo-MPDC are used to refine the pharmacophore model of the transporter binding site.
Collapse
Affiliation(s)
- R J Bridges
- Department of Pharmaceutical Sciences, University of Montana, Missoula 59812
| | | | | | | | | |
Collapse
|
34
|
Griffiths R, Dunlop J, Gorman A, Senior J, Grieve A. L-trans-pyrrolidine-2,4-dicarboxylate and cis-1-aminocyclobutane-1,3-dicarboxylate behave as transportable, competitive inhibitors of the high-affinity glutamate transporters. Biochem Pharmacol 1994; 47:267-74. [PMID: 7905733 DOI: 10.1016/0006-2952(94)90016-7] [Citation(s) in RCA: 66] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
The ability of two conformationally restricted analogues of L-glutamate to function as non-transportable inhibitors of plasma membrane L-glutamate transport was investigated in primary cultures of cerebellar granule cells and cortical astrocytes. L-trans-Pyrrolidine-2,4-dicarboxylic acid (L-trans-PDC) and cis-1-aminocyclobutane-1,3-dicarboxylic acid (cis-ACBD) behaved as linear competitive inhibitors of the uptake of D-[3H]aspartate (used as a non-metabolizable analogue of L-glutamate) exhibiting Ki values between 40 and 145 microM; L-trans-PDC being the more potent inhibitor in each preparation. However, both L-trans-PDC and cis-ACBD, over a concentration range of 1 microM-5 mM, dose-dependently stimulated the release of exogenously supplied D-[3H]aspartate from granule cells maintained in a continuous superfusion system. The stimulated release was independent of extracellular calcium ions; essentially superimposable dose-response profiles being obtained in the absence and presence of 1.3 mM CaCl2 and yielding EC50 values of 16-25 microM and 180-220 microM for L-trans-PDC and cis-ACBD, respectively. Stimulated release of D-[3H]aspartate was unaffected by either 300 microM D-(-)-2-amino-5-phosphonopentanoic acid [D-APV; a selective antagonist of the N-methyl-D-aspartate (NMDA) receptor] or by 25 microM 6-cyano-7-nitroquinoxaline-2,3-dione [CNQX; a selective antagonist of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor]. The release of D-[3H]-aspartate following stimulation by either L-trans-PDC or cis-ACBD was however markedly attenuated following substitution in the superfusion medium of sodium ions by choline ions. Taken together, these results support an action of L-trans-PDC and cis-ACBD consistent with that of being competitive substrates rather than non-transportable blockers of the plasma membrane L-glutamate uptake system.
Collapse
Affiliation(s)
- R Griffiths
- Division of Cell of Molecular Biology, School of Biological and Medical Sciences, University of St. Andrews, Fife, U.K
| | | | | | | | | |
Collapse
|
35
|
Dewar D, McCulloch J. Abnormalities in Non-Cholinergic Neurotransmitter Systems in Alzheimer’s Disease. DEMENTIA 1994. [DOI: 10.1007/978-1-4615-6805-6_11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
|
36
|
Farooqui AA, Horrocks LA. Excitotoxicity and neurological disorders: involvement of membrane phospholipids. INTERNATIONAL REVIEW OF NEUROBIOLOGY 1994; 36:267-323. [PMID: 7822118 DOI: 10.1016/s0074-7742(08)60306-2] [Citation(s) in RCA: 86] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Excitatory amino acids and their receptors play an important role in membrane phospholipid metabolism. Persistent stimulation of excitatory amino acid receptors by glutamate may be involved in neurodegenerative diseases and brain and spinal cord trauma. The molecular mechanism of neurodegeneration induced by excitatory amino acids is, however, not known. Excitotoxin-induced calcium entry causes the stimulation of phospholipases and lipases. These enzymes act on neural membrane phospholipids and their stimulation results in accumulation of free fatty acids, diacylglycerols, eicosanoids, and lipid peroxides in neurodegenerative diseases and brain and spinal cord trauma. Other enzymes, such as protein kinase C and calcium-dependent proteases, may also contribute to the neuronal injury. Excitotoxin-induced alterations in membrane phospholipid metabolism in neurodegenerative diseases and neural trauma can be studied in animal and cell culture models. These models can be used to study the molecular mechanisms of the neurodegenerative processes and to screen the efficacy of therapeutic drugs.
Collapse
Affiliation(s)
- A A Farooqui
- Department of Medical Biochemistry, Ohio State University, Columbus 43210
| | | |
Collapse
|
37
|
Tanaka K. Pharmacological characterization of a cloned rat glutamate transporter (GluT-1). BRAIN RESEARCH. MOLECULAR BRAIN RESEARCH 1994; 21:167-70. [PMID: 7909350 DOI: 10.1016/0169-328x(94)90390-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/27/2023]
Abstract
Pharmacological properties of a cDNA clone encoding a high affinity, Na(+)-dependent L-glutamate transporter (GluT-1) were examined using Xenopus oocytes. L-[3H]glutamate transport was inhibited by the putative endogenous substrates L-aspartate (Ki = 65 microM) and L-glutamate (Ki = 70 microM). L-Homocysteate did not significantly inhibit high-affinity glutamate transport (Ki = 2.7 mM). Of the previously identified uptake inhibitors, DL-threo-beta-hydroxyaspartate (Ki = 65 microM), L-cysteine sulfinate (Ki = 80 microM), beta-glutamate (Ki = 475 microM) and L-aspartate-beta-hydroxamate (Ki = 950 microM) inhibited L-glutamate uptake. The other L-glutamate uptake blockers examined, including dihydrokainate, L-alpha-aminoadipate and SITS, weakly inhibited uptake of L-glutamate with Ki values in excess of 1 mM. These features of the inhibitor sensitivities of GluT-1 transport show that GluT-1 is less sensitive to these agents than previously characterized glutamate transporters in rat brain, suggesting that GluT-1 is a novel glutamate transporter with a unique pharmacologic profile.
Collapse
Affiliation(s)
- K Tanaka
- Laboratory for Neural Networks, Institute of Physical and Chemical Research (RIKEN), Saitama, Japan
| |
Collapse
|
38
|
Palmer AM, Burns MA. Preservation of redox, polyamine, and glycine modulatory domains of the N-methyl-D-aspartate receptor in Alzheimer's disease. J Neurochem 1994; 62:187-96. [PMID: 8263519 DOI: 10.1046/j.1471-4159.1994.62010187.x] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
This study used [3H]dizocilpine ([3H]MK-801) binding to the N-methyl-D-aspartate (NMDA) receptor to examine redox, polyamine, and glycine modulatory sites in membranes derived from the superior frontal and the superior temporal cortex of patients with Alzheimer's disease. In control subjects the competitive polyamine site antagonist arcaine inhibited [3H]dizocilpine binding in a dose-dependent fashion and this curve was shifted to the right by the addition of 50 microM spermidine. Arcaine inhibition of binding was more potent in the temporal cortex than in the frontal cortex, in both the absence and presence of 50 microM spermidine. In Alzheimer's disease, arcaine inhibition of [3H]dizocilpine binding (in both the absence and the presence of spermidine) was not different from control in either of the two brain areas examined. The sulfhydryl redox site of the NMDA receptor was assessed using the oxidizing agent 5,5'-dithio-bis(2-nitrobenzoic acid), which inhibited binding in a dose-dependent fashion. This inhibition was similar in patients with Alzheimer's disease and control subjects. Glycine-stimulated [3H]dizocilpine binding was also unaffected in patients with Alzheimer's disease. However, in the temporal cortex there was a significant age-associated decline in [3H]dizocilpine binding in the presence of 100 microM glutamate (Rs = -0.71) and 100 microM glutamate plus 30 microM glycine (Rs = -0.90). There was also an age-related increase in arcaine IC50 (which reflects an age-related decrease in arcaine affinity) in the frontal cortex, determined both in the absence (Rs = 0.83) and the presence (Rs = 0.79) of spermidine. These data indicate that the NMDA receptor and its modulatory redox, polyamine, and glycine subsites are intact in patients with Alzheimer's disease and that the modulatory activity of polyamine and glycine sites decline with aging.
Collapse
Affiliation(s)
- A M Palmer
- Department of Psychiatry, University of Pittsburgh School of Medicine, Pennsylvania
| | | |
Collapse
|
39
|
Abstract
A complementary DNA clone encoding a transporter for glutamate has been isolated from mouse brain, and its functional properties have been examined in Xenopus oocytes. The transporter displays high affinity for glutamate (Km = 72 microM) and is dependent on external Na+. The cDNA sequence predicts a protein of 543 amino acids with 6 potential transmembrane domains. Northern blot analysis indicates the mRNA encoding the glutamate transporter is expressed both in the brain and in peripheral tissues.
Collapse
Affiliation(s)
- K Tanaka
- Laboratory for Neural Networks, Institute of Physical and Chemical Research, RIKEN, Saitama, Japan
| |
Collapse
|
40
|
Abstract
Removal of glutamate from the synaptic cleft is an essential component of the transmission process at glutamatergic synapses. This requirement is fulfilled by transporters that have a high affinity for glutamate and exhibit a unique coupling to Na+, K+ and OH- ions. Independently, three groups have succeeded in cloning cDNAs encoding high-affinity Na(+)-dependent glutamate transporters. These transporters are structurally distinct from previously characterized neurotransmitter transporters and show sequence identity with prokaryotic glutamate and dicarboxylate transporters. In addition, they exhibit significant differences in their structure, function and tissue distribution. This review compares and contrasts these differences, and incorporates into the existing body of knowledge these new breakthroughs.
Collapse
Affiliation(s)
- Y Kanai
- Dept of Medicine, Brigham and Women's Hospital, Boston, MA
| | | | | |
Collapse
|
41
|
Myhrer T. Animal models of Alzheimer's disease: glutamatergic denervation as an alternative approach to cholinergic denervation. Neurosci Biobehav Rev 1993; 17:195-202. [PMID: 8515902 DOI: 10.1016/s0149-7634(05)80150-2] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that severely reduces lifespan. In this article, a new, glutamatergic denervation model of AD is presented as a supplement to the well known cholinergic one, because these models are trying to mimic different aspects of the pathology in AD. Impaired memory and disorientation are prominent features in the symptomatology of AD. In searching for neurochemical systems associated with the initial cognitive disorders of AD, a reorientation from cholinergic to glutamatergic systems is suggested. Results from recent behavioral studies of damage to the temporal and entorhinal cortices in rats imply that these structures are strongly involved in mnemonic function. Findings from Alzheimer brains and laboratory animals indicate that major losses of glutamatergic receptors may underly the cognitive impairment seen in AD patients. A growing body of evidence appears to support a glutamatergic hypothesis of AD. Possible pharmacological approaches are suggested.
Collapse
Affiliation(s)
- T Myhrer
- Norwegian Defence Research Establishment, Division for Environmental Toxicology, Kjeller
| |
Collapse
|
42
|
Francis PT, Sims NR, Procter AW, Bowen DM. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem 1993; 60:1589-604. [PMID: 8473885 DOI: 10.1111/j.1471-4159.1993.tb13381.x] [Citation(s) in RCA: 173] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Affiliation(s)
- P T Francis
- Miriam Marks Department of Neurochemistry, Institute of Neurology, London, England
| | | | | | | |
Collapse
|
43
|
Fishkin RJ, Ince ES, Carlezon WA, Dunn RW. D-cycloserine attenuates scopolamine-induced learning and memory deficits in rats. BEHAVIORAL AND NEURAL BIOLOGY 1993; 59:150-7. [PMID: 8476382 DOI: 10.1016/0163-1047(93)90886-m] [Citation(s) in RCA: 88] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
The muscarinic antagonist scopolamine (SCOP; 1.0 mg/kg, ip) impaired both the acquisition of a learning task in the Morris water maze (MWM) and choice accuracy in the T-maze reinforced alternation procedure in rats. Acetylcholinesterase inhibitors (AChEIs) have been shown to attenuate these deficits. D-Cycloserine (DCS), a partial agonist at the strychnine-insensitive glycine site on the N-methyl-D-aspartate (NMDA) receptor complex, was investigated for its effects on SCOP-induced dementia in the MWM and T-maze paradigms. Combined administration of SCOP and DCS (3.0, 10.0, or 30.0 mg/kg, ip; 30 min pretreat) significantly reversed SCOP-induced deficits in the T-maze as measured by percentage correct choices. In addition, DCS (3.0 or 10.0 mg/kg, ip) significantly attenuated SCOP-induced deficits in the MWM as measured by latency to find the submerged platform. For comparison, the long-acting acetylcholinesterase inhibitor galanthamine (GAL) was tested in the T-maze (1.25, 2.5, or 5.0 mg/kg, ip) and the MWM (2.5 or 5.0 mg/kg, ip). GAL attenuated SCOP-induced deficits in both learning and memory models similar to DCS. These data suggest that the strychnine-insensitive partial glycine agonist, D-cycloserine, may be efficacious in disease states of central cholinergic hypofunction such as Alzheimer's disease.
Collapse
Affiliation(s)
- R J Fishkin
- Hoechst-Roussel Pharmaceuticals, Inc., Somerville, New Jersey 08876-1258
| | | | | | | |
Collapse
|
44
|
Reyes PF, Deems DA, Suarez MG. Olfactory-related changes in Alzheimer's disease: a quantitative neuropathologic study. Brain Res Bull 1993; 32:1-5. [PMID: 8319097 DOI: 10.1016/0361-9230(93)90310-8] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023]
Abstract
Neuropathological studies of 10 confirmed cases of Alzheimer's disease (AD) revealed increased numbers of neurofibrillary tangles and neuritic plaques in olfactory cortex compared to other brain regions. This was most evident when AD tissues were compared to tissues from seven gender- and age-matched controls. In the AD cases, examination of other brain regions which receive olfactory projections also revealed high concentrations of neuritic plaques and neurofibrillary tangles. These data also confirm previous observations that neurofibrillary tangle formation is more prevalent than neuritic plaque formation in AD. This is the first quantitative neuropathological study that demonstrates significant damage to various components of the central olfactory apparatus in AD. Our data suggest that damage to these areas may be related to the behavioral, emotional, and cognitive abnormalities commonly observed in affected patients. The use of antemortem evaluation of the olfactory system as a diagnostic tool for AD is discussed.
Collapse
Affiliation(s)
- P F Reyes
- Department of Neurology and Pathology, Jefferson Medical College of Thomas Jefferson University, Philadelphia, PA 19107
| | | | | |
Collapse
|
45
|
|
46
|
De Lacoste MC, White CL. The role of cortical connectivity in Alzheimer's disease pathogenesis: a review and model system. Neurobiol Aging 1993; 14:1-16. [PMID: 8450928 DOI: 10.1016/0197-4580(93)90015-4] [Citation(s) in RCA: 166] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Here we review current evidence in support of the cortical disconnection/cortical connectivity model of Alzheimer disease (AD) pathogenesis, a model which predicts that one of the first events in AD is damage to the entorhinal cortex and/or subiculum resulting in the disconnection of the hippocampal formation and neocortex, and the subsequent progression of the disease in a stepwise fashion along cortico-cortical connections. Much of the evidence for this model has been obtained from studies involving the limbic system where investigators have demonstrated a precise correspondence between established patterns of connectivity and the degenerative changes associated with AD. In addition, some studies of the distribution of neuritic plaques (NP) and neuro-fibrillary tangles (NFT) in the neocortex and subcortical structures have yielded corroborative data. The validity of the cortical disconnection/connectivity model in the neocortex remains to be established or refuted. We propose that testing of this model can be accomplished with systematic studies of the laminar and regional distribution of NP and NFT in a series of sequentially interconnected cytoarchitectural regions that also form part of two functional hierarchies--the paralimbic and occipitotemporal visual systems. To adequately control for variation between brains affected by AD, it is imperative that such studies be conducted in a large but varied population of AD cases exhibiting differences in several variables, including clinical and/or neuropathological severity of the disease, temporal duration of the disease, and clinical/neuropsychological profile. We believe that further understanding of the relationship between characteristic AD pathology and intrinsic anatomico-functional circuits will contribute not only to our comprehension of AD pathogenesis but also to our general knowledge of the human brain.
Collapse
Affiliation(s)
- M C De Lacoste
- Department of Obstetrics and Gynecology, Yale University Medical School, New Haven, CT 06510
| | | |
Collapse
|
47
|
Rao G, Barnes CA, McNaughton BL. Effects of age on L-glutamate-induced depolarization in three hippocampal subfields. Neurobiol Aging 1993; 14:27-33. [PMID: 8095701 DOI: 10.1016/0197-4580(93)90017-6] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The effects of aging on the translation of L-glutamate-induced depolarization into hippocampal neuronal firing frequency were studied in vitro. L-glutamate was iontophoretically-applied to the somatic region of extracellularly recorded single units. In none of the three principal hippocampal subfields (fascia dentata, CA3, and CA1) were there any effects of age on neuronal sensitivity to L-glutamate. Because there are pronounced, region-specific age effects on AMPA sensitivity (3), these results are in agreement with the conclusions of other investigators that the depolarization caused by exogenously applied L-glutamate probably exerts its effects through nonsynaptic mechanisms. These mechanisms, however, which lead to powerful depolarization and action potentials in hippocampal cells, are unaffected by age.
Collapse
Affiliation(s)
- G Rao
- Arizona Research Laboratories Division of Neural Systems, Memory and Aging, University of Arizona, Tucson 85724
| | | | | |
Collapse
|
48
|
Storck T, Schulte S, Hofmann K, Stoffel W. Structure, expression, and functional analysis of a Na(+)-dependent glutamate/aspartate transporter from rat brain. Proc Natl Acad Sci U S A 1992; 89:10955-9. [PMID: 1279699 PMCID: PMC50461 DOI: 10.1073/pnas.89.22.10955] [Citation(s) in RCA: 868] [Impact Index Per Article: 27.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022] Open
Abstract
Transport systems specific for L-glutamate and L-aspartate play an important role in the termination of neurotransmitter signals at excitatory synapses. We describe here the structure and function of a 66-kDa glycoprotein that was purified from rat brain and identified as an L-glutamate/L-aspartate transporter (GLAST). A GLAST-specific cDNA clone was isolated from a rat brain cDNA library. The cDNA insert encodes a polypeptide with 543 amino acid residues (59,697 Da). The amino acid sequence of GLAST suggests a distinctive structure and membrane topology, with some conserved motifs also present in prokaryotic glutamate transporters. The transporter function has been verified by amino acid uptake studies in the Xenopus laevis oocyte system. GLAST is specific for L-glutamate and L-aspartate, shows strict dependence on Na+ ions, and is inhibited by DL-threo-3-hydroxy-aspartate. In situ hybridization reveals a strikingly high density of GLAST mRNA in the Purkinje cell layer of cerebellum, presumably in the Bergmann glia cells, and a less dense distribution throughout the cerebrum. These data suggest that GLAST may be involved in the regulation of neurotransmitter concentration in central nervous system.
Collapse
Affiliation(s)
- T Storck
- Institute for Biochemistry, Medical Faculty, University of Cologne, Federal Republic of Germany
| | | | | | | |
Collapse
|
49
|
Francis PT, Pangalos MN, Bowen DM. Animal and drug modelling for Alzheimer synaptic pathology. Prog Neurobiol 1992; 39:517-45. [PMID: 1529103 DOI: 10.1016/0301-0082(92)90005-y] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Affiliation(s)
- P T Francis
- Miriam Marks Department of Neurochemistry, Institute of Neurology, London, U.K
| | | | | |
Collapse
|
50
|
Advokat C, Pellegrin AI. Excitatory amino acids and memory: evidence from research on Alzheimer's disease and behavioral pharmacology. Neurosci Biobehav Rev 1992; 16:13-24. [PMID: 1553102 DOI: 10.1016/s0149-7634(05)80046-6] [Citation(s) in RCA: 49] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
The excitatory amino acid transmitter (EAA) system is believed to play a crucial role in a variety of physiological processes related to neuronal plasticity. Substantial neurophysiological evidence suggests that, under normal physiological conditions. EAAs may be involved in mechanisms underlying learning and memory. However, overactivity of this system produces excitotoxic damage to neurons which is believed to be an etiological factor in various neurological conditions, such as epilepsy, and stroke-induced impairments. The fact that EAAs have been implicated in both, normal cognitive function and in degenerative neurological conditions suggests that they may contribute to the etiology of Alzheimer's disease (AD), because AD is characterized by memory deficits and specific histopathological signs of neuronal damage. This paper summarizes information regarding 1) the involvement of EAAs in Alzheimer's disease and 2) results from psychopharmacological studies of EAAs in laboratory animal models of learning. Investigations of the pathophysiology of AD indicate that glutamatergic deficits are associated with this syndrome. However, there is controversy concerning the nature of this defect. As a result, it is unclear whether it is a consequence of excitotoxic changes produced by glutamatergic overactivity or result from a decrease in glutamatergic function. Evidence from behavioral studies is consistent with the conclusion that EAAs may be involved in the acquisition of conditioned responses. However, in parallel with the clinical findings, learning impairments have been produced by treatments which either increase or decrease activity within this transmitter system. Therefore, although present results suggest that the EAAs play a role in cognition and in clinical syndromes in which such function is compromised, the specific nature of that role needs to be elucidated by future research.
Collapse
Affiliation(s)
- C Advokat
- Department of Psychology, Louisiana State University, Baton Rouge 70803
| | | |
Collapse
|